ChandraPBelaniMD

Oncology • Hershey, PA

Professor of Medicine Penn State Milton S. Hershey Medical Center Deputy Director Penn State Cancer Institute

Join to view full profile

Dr. Belani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Belani's full profile

Already have an account?

Office
500 University Dr
Hershey, PA 17033
Phone+1 717-531-6585

Fax+1 717-531-5076

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1985 - 1988
Icahn School of Medicine at Mount Sinai (North General)Residency, Internal Medicine, 1984 - 1985
University of MarylandResidency, Internal Medicine, 1982 - 1984
Sawai Man Singh Medical CollegeClass of 1977

Certifications & Licensure

PA State Medical License 1988 - 2026
MD State Medical License 1984 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Pittsburgh Magazine Castle Connolly, 2005-2007

Clinical Trials

Gene Therapy in Treating Patients With Cancer of The Liver Start of enrollment: 1998 Feb 01
Terminated
Phase 1
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Start of enrollment: 1998 Jun 01
Completed
Phase 3
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors Start of enrollment: 1998 Mar 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 1999 Dec 01
Withdrawn
Phase 1
Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors Start of enrollment: 1999 Dec 01
Withdrawn
Phase 1
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas Start of enrollment: 2004 Jul 01
Completed
Phase 1
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer Start of enrollment: 2006 Aug 09
Terminated
Phase 2
Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2007 Jun 01
Withdrawn
Phase 2
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2007 May 01
Completed
Phase 2
Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2008 Apr 01
Terminated
Phase 1
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2008 Sep 01
Terminated
Phase 1, Phase 2
Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2008 Oct 01
Terminated
Phase 1
A Trial for Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Dec 01
Phase II Avastin Trial for Stage IIIB/IV NSCLC Start of enrollment: 2008 Oct 01
Terminated
Phase 2
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Start of enrollment: 2009 Jul 16
Completed
Phase 2
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
Completed
Phase 1, Phase 2
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18
Completed
Phase 2
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2011 Jan 01
Completed
Phase 1
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 1
Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer Start of enrollment: 2012 Dec 01
Withdrawn
Not Applicable
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 1
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2012 Jul 24
Completed
Phase 1
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
Completed
Phase 2
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2012 Dec 06
Completed
Phase 1
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2014 Jul 21
Active, not recruiting
Phase 2
Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung Start of enrollment: 2016 Apr 10
Terminated
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Characterization of effective, simple, and low-cost precipitation methods for depleting abundant plasma proteins to enhance the depth and breadth of plasma proteomics.
Shawn J Rice, Chandra P Belani
Proteomics. 2024-08-01
3 citations
Natural History and Real-World Treatment Outcomes for Patients With NSCLC HavingExon 20 Insertion Mutation: An International Association for the Study of Lung Cancer-A...
Madhusmita Behera, Renjian Jiang, Zhonglu Huang, Becky Bunn, Murry W Wynes
JTO Clinical and Research Reports. 2024-06-01
1 citations
Design of experiments approach for systematic optimization of a single-shot diaPASEF plasma proteomics workflow applicable for high-throughput.
Shawn J Rice, Chandra P Belani
Proteomics. Clinical Applications. 2024-01-01

Lectures

Emerging Strategies in Treatment of Non−Small-Cell Lung Cancer and Head & Neck Cancer 2012
CancerNet, LLC, Atlanta, Georgia - 6/16/2012
5th Symposium on Emerging Treatments & Advances in Novel Cancer Therapies for Practicing Physicians & Healthcare Professionals
CancerNet, LLC, Dallas, Texas - 1/18/2012

Press Mentions

Serplulimab First Anti-PD-1 to Improve Overall Survival in Extensive-Stage SCLCJune 6th, 2022
Lung Cancer COVID-19 Guidance AvailableJuly 23rd, 2020
International Association for the Study of Lung Cancer Appoints Chandra P. Belani, M.D. As New Chief Science OfficerNovember 25th, 2019
Join now to see all

Grant Support

Clinical Trial: PI &Pharmacokinetic Study Of Drug For Solid Tumors &LymphomasNational Center For Research Resources2009
Clinical Trial: PI &Pharmacokinetic Single Agent Study Of Drug In PTS W Adv MaliNational Center For Research Resources2009
Clinical Trial: A Phase I Study In Advanced Solid Malignancies (Nci 7967)National Center For Research Resources2009
Phase I Clinical Trials Of Novel Anticancer AgentsNational Cancer Institute2003–2006
Adenovirus P53 Construct For Hepatocellular CarcinomaNational Center For Research Resources2000–2002
Filgrastim Sd/01 PTS W/ NON Small Cell Lung Cancer Or Thoracic TumorsNational Center For Research Resources1999–2002
Phase I Pharmacokinetic Study Of Carboplatin In Combo With Weekly PaclitaxelNational Center For Research Resources1998–2002
Filgrastim For Treatment Of Nonsmall Cell Lung Cancer Or Thoracic TumorsNational Center For Research Resources1999
Pharmacokinetic Study Of Taxol &Carboplatin With Filgrastim In Lung CarcinomaNational Center For Research Resources1997
Phase I Study Of Docetaxel And Carboplatin In Combination ChemotherapyNational Center For Research Resources1996–1997
Phase II Study Of IV Administered Tirapazamine PLUS Cisplatin In NsclcNational Center For Research Resources1996
Phase I/II Pharmacokinetic Study Of Taxol And Carboplatin With FilgrastimNational Center For Research Resources1996